Prosecution Insights
Last updated: August 08, 2026
Application No. 18/666,032

METHODS FOR REDUCING IMPURITIES IN SILK FIBROIN PREPARATIONS

Non-Final OA §112§DOUBLEPATENT§DP
Filed
May 16, 2024
Priority
May 02, 2022 — provisional 63/337,325 +3 more
Examiner
MENON, KRISHNAN S
Art Unit
1777
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Cocoon Biotech Inc.
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
1y 0m
Est. Remaining
71%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
900 granted / 1505 resolved
-5.2% vs TC avg
Moderate +12% lift
Without
With
+11.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
71 currently pending
Career history
1568
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
40.5%
+0.5% vs TC avg
§102
23.9%
-16.1% vs TC avg
§112
24.0%
-16.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1505 resolved cases

Office Action

§112 §DOUBLEPATENT §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 4-8 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 1 recites that the only solvent in the process is water. These claims recite added ethanol, which changes the scope of claim 1. . Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-15 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims of U.S. Patent No. 120,24,538, or USP ‘538 in view of Zhang et al, “Accelerated desalting and purification of silk fibroin in a CaCl2-EtOH-H2O ternary system by excess isopropanol extraction,” J Chem Technol Biotechnol 2021; 96: 1176–1186. Although the claims at issue are not identical, they are not patentably distinct from each other because: see the table below: Instant Claim Reference Claim Comments 1 1,9 Instant claim broader in scope 2 3 Implied or inherent from the number of exchanges 3 1, 9 4 1, 9 In view of Zhang, et al, known in the art as best: see the section on influence of CaCl2. 5 1,9 Do - 6 1,9 Do - 7 1,9 in view of Altman, and residual salt is inherent 8 1,9 Do - 9 2 10 3 11 4 12 5 13 6 14 7 15 8 For claims 4-8, use of CaCl2/EtOH/water in place of LiBr/water is obvious because Zhang teaches that this solvent is better for the purification of silk fibrinogen faster dialysis and high recovery – see abstract, tables and the section on “influence of CaCl2…” The 1:2:8 ratio is seen in “preparation of silk fibrinogen solution.” Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KRISHNAN S MENON whose telephone number is (571)272-1143. The examiner can normally be reached Flexible, but generally Monday-Friday: 8:00AM-4:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Vickie Kim can be reached on 5712720579. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KRISHNAN S MENON/Primary Examiner, Art Unit 1777
Read full office action

Prosecution Timeline

May 16, 2024
Application Filed
May 07, 2026
Non-Final Rejection mailed — §112, §DOUBLEPATENT, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12691422
Filtration membrane and method of production thereof
4y 7m to grant Granted Jul 28, 2026
Patent 12691469
ULTRASONIC EXTRACTION DEVICE FOR PLANT POLYPHENOLS
2y 7m to grant Granted Jul 28, 2026
Patent 12685968
WASTEWATER TREATMENT METHOD
2y 7m to grant Granted Jul 21, 2026
Patent 12673301
MULTILAYER POROUS MEMBRANE WITH INCOMPATIBLE RESINS
3y 8m to grant Granted Jul 07, 2026
Patent 12673300
COMPOSITE SEMIPERMEABLE MEMBRANE, AND SPIRAL MEMBRANE ELEMENT
2y 4m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
71%
With Interview (+11.5%)
3y 3m (~1y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1505 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month